WallStSmart

Edwards Lifesciences Corp (EW)vsS&P Global Inc (SPGI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

S&P Global Inc generates 153% more annual revenue ($15.34B vs $6.07B). SPGI leads profitability with a 29.1% profit margin vs 17.7%. SPGI appears more attractively valued with a PEG of 1.50. SPGI earns a higher WallStSmart Score of 67/100 (B-).

EW

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.8
Piotroski: 2/9

SPGI

Strong Buy

67

out of 100

Grade: B-

Growth: 8.0Profit: 8.0Value: 10.0Quality: 6.0
Piotroski: 5/9Altman Z: 1.97
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWSignificantly Overvalued (-544.4%)

Margin of Safety

-544.4%

Fair Value

$12.31

Current Price

$82.67

$70.36 premium

UndervaluedFair: $12.31Overvalued
SPGIUndervalued (+40.5%)

Margin of Safety

+40.5%

Fair Value

$687.02

Current Price

$408.48

$278.54 discount

UndervaluedFair: $687.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW1 strengths · Avg: 8.0/10
Operating MarginProfitability
23.7%8/10

Strong operational efficiency at 23.7%

SPGI5 strengths · Avg: 8.8/10
Operating MarginProfitability
38.3%10/10

Strong operational efficiency at 38.3%

Market CapQuality
$124.51B9/10

Large-cap with strong market position

Profit MarginProfitability
29.1%9/10

Keeps 29 of every $100 in revenue as profit

EPS GrowthGrowth
32.0%8/10

Earnings expanding 32.0% YoY

Free Cash FlowQuality
$1.70B8/10

Generating 1.7B in free cash flow

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.144/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
45.7x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-76.6%2/10

Earnings declined 76.6%

SPGI2 concerns · Avg: 4.0/10
P/E RatioValuation
28.0x4/10

Moderate valuation

Altman Z-ScoreHealth
1.974/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.

Bull Case : SPGI

The strongest argument for SPGI centers on Operating Margin, Market Cap, Profit Margin. Profitability is solid with margins at 29.1% and operating margin at 38.3%.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.

Bear Case : SPGI

The primary concerns for SPGI are P/E Ratio, Altman Z-Score.

Key Dynamics to Monitor

SPGI carries more volatility with a beta of 1.22 — expect wider price swings.

EW is growing revenue faster at 13.3% — sustainability is the question.

SPGI generates stronger free cash flow (1.7B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SPGI scores higher overall (67/100 vs 55/100), backed by strong 29.1% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

S&P Global Inc

FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA

S&P Global Inc. is an American publicly traded corporation headquartered in Manhattan, New York City. Its primary areas of business are financial information and analytics.

Visit Website →

Want to dig deeper into these stocks?